Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002052113-25-001839
Filing Date
2025-04-29
Accepted
2025-04-29 08:03:25
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5999
2 PowerOfAttorney.txt EX-24 2753
3 Item_7.txt EX-99 405
  Complete submission text file 0002052113-25-001839.txt   11118
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Subject) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91312 | Film No.: 25882768
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 50 HUDSON YARDS NEW YORK NY 10001
Business Address 50 HUDSON YARDS NEW YORK NY 10001 (212) 810-5800
BlackRock, Inc. (Filed by) CIK: 0002012383 (see all company filings)

EIN.: 991116001 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6211 Security Brokers, Dealers & Flotation Companies
(CF Office: 02 Finance)